Our Approach

AVEO is committed to developing high value, novel cancer therapeutics which address major unmet medical needs in oncology. Through a combination of internal drug discovery and selective in-licensing of targeted therapeutics, AVEO is building a diversified product pipeline and moving toward its vision of becoming a fully integrated biopharmaceutical company.  AVEO's corporate partners include Merck & Co., Schering-Plough, Mitsubishi, Kirin Pharmaceuticals and OSI Pharmaceuticals.

AVEO continues to seek collaborations with partners who share AVEO’s vision and is actively seeking to co-develop, in-license or acquire investigational cancer compounds for which the application of AVEO’s technology and expertise in cancer biology and genetics can provide unique insight and a competitive edge in development.

» back to top